Biohaven Pharmaceutical (NYSE:BHVN) Insider Sells $863,100.00 in Stock

Biohaven Pharmaceutical (NYSE:BHVN) insider Robert Berman sold 35,000 shares of the stock in a transaction dated Tuesday, April 10th. The stock was sold at an average price of $24.66, for a total transaction of $863,100.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Robert Berman also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, March 12th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $30.11, for a total transaction of $1,053,850.00.
  • On Monday, February 12th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $30.42, for a total transaction of $1,064,700.00.

NYSE:BHVN traded down $0.33 during mid-day trading on Thursday, reaching $27.27. The stock had a trading volume of 280,615 shares, compared to its average volume of 735,043. Biohaven Pharmaceutical has a twelve month low of $16.50 and a twelve month high of $39.51. The company has a market cap of $949.06 and a P/E ratio of -5.48.

Biohaven Pharmaceutical (NYSE:BHVN) last issued its earnings results on Tuesday, March 6th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.33) by $0.58. analysts predict that Biohaven Pharmaceutical will post -4.34 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. purchased a new position in Biohaven Pharmaceutical in the third quarter valued at about $1,431,000. Susquehanna International Group LLP purchased a new position in Biohaven Pharmaceutical in the third quarter valued at about $302,000. Candriam Luxembourg S.C.A. purchased a new position in Biohaven Pharmaceutical in the fourth quarter valued at about $2,158,000. Endurant Capital Management LP purchased a new position in Biohaven Pharmaceutical in the fourth quarter valued at about $278,000. Finally, Wells Fargo & Company MN purchased a new position in Biohaven Pharmaceutical in the third quarter valued at about $1,339,000. 61.84% of the stock is owned by institutional investors.

Several equities research analysts have recently weighed in on BHVN shares. Piper Jaffray reiterated a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Monday, March 26th. Canaccord Genuity restated a “buy” rating and issued a $34.00 price objective (down previously from $39.00) on shares of Biohaven Pharmaceutical in a research report on Monday, March 26th. Zacks Investment Research upgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research report on Friday, March 9th. Needham & Company LLC restated a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Thursday, February 22nd. Finally, Barclays downgraded shares of Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $30.00 to $25.00 in a research report on Thursday, April 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $37.14.

COPYRIGHT VIOLATION WARNING: “Biohaven Pharmaceutical (NYSE:BHVN) Insider Sells $863,100.00 in Stock” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://ledgergazette.com/2018/04/19/insider-selling-biohaven-pharmaceutical-bhvn-insider-sells-35000-shares-of-stock.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply